Search Engine Land
  • SEO
    • > All SEO
    • > What Is SEO?
    • > SEO Periodic Table
    • > Google: SEO
    • > Bing SEO
    • > Google Algorithm Updates
  • PPC
    • > All PPC
    • > What is PPC?
    • > Google Ads
    • > Microsoft Ads
    • > The Periodic Tables of PPC
  • Focuses
    • > Local
    • > Commerce
    • > Shopify SEO Guide
    • > Content
    • > Email Marketing Periodic Table
    • > Social Media Marketing
    • > Analytics
    • > Search Engine Land Awards
    • > All Focuses
  • SMX
  • Webinars
  • Intelligence Reports
  • White Papers
  • About
    • > About Search Engine Land
    • > Newsletter
    • > Third Door Media
    • > Advertise

Processing...Please wait.

Search Engine Land » Channel » Content » FDA Warnings To Pharma Caused Big Drop In Search Ads

FDA Warnings To Pharma Caused Big Drop In Search Ads

The US Food & Drug Administration (FDA) issued warning letters issued in late March, 2009 to a number of big pharmaceutical companies, saying that their search ads were misleading and didn’t contain the required disclosure information mandated by US federal regulations. As one might have expected this caused the companies to temporarily pull their SEM […]

Greg Sterling on October 2, 2009 at 10:31 am

The US Food & Drug Administration (FDA) issued warning letters issued in late March, 2009 to a number of big pharmaceutical companies, saying that their search ads were misleading and didn’t contain the required disclosure information mandated by US federal regulations. As one might have expected this caused the companies to temporarily pull their SEM campaigns and resulted in a “59% drop in sponsored link exposures,” according to comScore:

An analysis of exposure to branded URLs within comScore’s data revealed that substantial declines occurred immediately following the letters being sent on March 26. Sponsored link exposures dropped 59 percent from 10.5 million during the week ending March 29 to 4.3 million during the week ending April 5. Declines in sponsored link exposures not only occurred in the weeks immediately following the letters, but continued over the next several months, plummeting 84 percent overall from March to June.

This basically means that they suspended their search ads while they tried to figure out how to comply with the FDA’s rules. Annually the pharmaceutical industry represents almost a billion dollars in online ad spending in the US. Here are the IAB’s numbers for 2008:

Picture 220

ComScore also said that organic sites promoting pharma products were also re-evaluated by the companies and experienced a traffic decline for a period of time:

Vanity and unbranded link exposures also experienced a decline, on average, across brands during the same period, although these methods were not under scrutiny in the FDA letters. Unbranded sites, which give additional information on the condition and treatment but do not directly promote the brand drug, declined 35-percent March to June to slightly more than one million exposures. Vanity URLs, which make no mention of a specific brand while generically describing a health condition but then redirect to the brand or drug’s website, declined 11 percent in June to 3.2 million average exposures versus March.

One of the challenges for the pharma industry in doing SEM for specific drugs is writing ad copy that is legally compliant, with a very limited amount of space in which to operate. It’s kind of absurd in a way. It thus may be that the industry will have to target conditions or ailments in paid-search ads and not mention specific drugs at all.


Opinions expressed in this article are those of the guest author and not necessarily Search Engine Land. Staff authors are listed here.


New on Search Engine Land

    How privacy changes affect B2B paid search marketing

    Google search results spam for ‘Bill Slawski obituary’ shows the dark side of SEO

    New mobile Google ad experiment puts favicon in-line with display URL

    Google launches video health tools to help publisher monetization

    SEO pioneer and expert Bill Slawski passes away

About The Author

Greg Sterling
Greg Sterling is a Contributing Editor to Search Engine Land, a member of the programming team for SMX events and the VP, Market Insights at Uberall.

Related Topics

ContentRegulationSEO

Get the daily newsletter search marketers rely on.

Processing...Please wait.

See terms.

ATTEND OUR EVENTS

Learn actionable search marketing tactics that can help you drive more traffic, leads, and revenue.

March 8-9, 2022: Master Classes (virtual)

June 14-15, 2022: SMX Advanced (virtual)

November 15-16, 2022: SMX Next (virtual)

Learn More About Our SMX Events

Discover time-saving technologies and actionable tactics that can help you overcome crucial marketing challenges.

Start Discovering Now: Spring (virtual)

September 28-29, 2022: Fall (virtual)

Learn More About Our MarTech Events

Webinars

Take a Crawl, Walk, Run Approach to Multi-Channel ABM

Content Comes First: Transform Your Operations With DAM

Dominate Your Competition with Google Auction Insights and Search Intelligence

See More Webinars

Intelligence Reports

Enterprise SEO Platforms: A Marketer’s Guide

Enterprise Identity Resolution Platforms

Email Marketing Platforms: A Marketer’s Guide

Enterprise Sales Enablement Platforms: A Marketer’s Guide

Enterprise Digital Experience Platforms: A Marketer’s Guide

Enterprise Call Analytics Platforms: A Marketer’s Guide

See More Intelligence Reports

White Papers

Reputation Management For Healthcare Organizations

Unlock the App Marketing Potential of QR Codes

Realising the power of virtual events for demand generation

The Progressive Marketer’s Ultimate Events Strategy 2022 Worksheet

CMO Guide: How to Plan Smart and Pivot Fast

See More Whitepapers

Receive daily search news and analysis.

Processing...Please wait.

Topics

  • SEO
  • PPC

Our Events

  • Search Marketing Expo - SMX
  • MarTech

About

  • About Us
  • Contact
  • Privacy
  • Marketing Opportunities
  • Staff

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • Newsletters
  • RSS
  • Youtube

© 2022 Third Door Media, Inc. All rights reserved.